Advertisement

gynäkologie + geburtshilfe

, Volume 23, Supplement 1, pp 32–36 | Cite as

Individuell und präzise

Zielgerichtete Therapie des Mammakarzinoms

  • Cornelia LiedtkeEmail author
Fortbildung

Beim Mammakarzinom handelt es sich um eine sehr heterogene Erkrankung. Klinisch relevant sind vor allem Subgruppen, die durch die Expression zum Beispiel der Hormonrezeptoren definiert werden. Für sie gibt es zielgerichtete Therapieansätze.

Literatur

  1. 1.
    Perou CM et al. Molecular portraits of human breast tumours. Nature. 2000;;406:747–52.CrossRefGoogle Scholar
  2. 2.
    Liedtke C et al. Systemic Therapy of Advanced/Metastatic Breast Cancer - Current Evidence and Future Concepts. Breast Care (Basel). 2016;11:275–81CrossRefGoogle Scholar
  3. 3.
    Tripathy D et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904–15.CrossRefGoogle Scholar
  4. 4.
    Barroso-Sousa et al. Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer. Breast Care (Basel). 2016;11:167–73CrossRefGoogle Scholar
  5. 5.
    Baselga et al. Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. J Clin Oncol. 2018;36(suppl):LBA1006CrossRefGoogle Scholar
  6. 6.
    Gianni L et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32CrossRefGoogle Scholar
  7. 7.
    von Minckwitz et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377:122–31CrossRefGoogle Scholar
  8. 8.
    Harbeck et al. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET. J Clin Oncol. 2017;35:3046–54CrossRefGoogle Scholar
  9. 9.
    Thill M et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018. Breast Care (Basel). 2018;13:209–15CrossRefGoogle Scholar
  10. 10.
    Loi S et al. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzu-mab-resistant HER2-positive metastatic breast cancer: Results from the -PANACEA (IBCSG 45-13//KEYNOTE-014) study. SABCS. 2017;Abstr GS2-06Google Scholar
  11. 11.
    Iwata et al. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts. J Clin Oncol. 2018;36(suppl);Abstr 2501Google Scholar
  12. 12.
    Gluz O et al. (2009) Triple-negative breast cancer—current status and future directions. Ann Oncol. 2009;20:1913–27CrossRefGoogle Scholar
  13. 13.
    Carey L et al. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683–92CrossRefGoogle Scholar
  14. 14.
    Liedtke C et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–81CrossRefGoogle Scholar
  15. 15.
    Katz H, Alsharedi M. Immunotherapy in triple-negative breast cancer. Med Oncol. 2017;35:13CrossRefGoogle Scholar
  16. 16.
    Brahmer et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–68CrossRefGoogle Scholar
  17. 17.
    Loibl C et al. Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). J Clin Oncol. 2018;36(suppl);Abstr 104Google Scholar
  18. 18.
    Robson M et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377:523–33CrossRefGoogle Scholar
  19. 19.
    Litton JK et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. Randomized controlled trial. N Engl J Med. 2018;379:753–63CrossRefGoogle Scholar
  20. 20.
    Litton JK et al. Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). J Clin Oncol. 2018;36(suppl);Abstr 508Google Scholar
  21. 21.
    Lehmann BD et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016;11:e0157368CrossRefGoogle Scholar
  22. 22.
    Traina TA et al. Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018;36):884–90CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Gynäkologie mit BrustzentrumCharité-Universitätsmedizin BerlinBerlinDeutschland

Personalised recommendations